AzTrials
AzTrials

Non-Hodgkin's LymphomaPhase 1NCT03074825

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

A Phase 1 study testing Chiauranib in people with Non-Hodgkin's Lymphoma, run by Chipscreen Biosciences, Ltd. at 1 site in China.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora B）、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma, in the meantime, exploring the latent biomarkers… Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Non-Hodgkin's Lymphoma
What is being tested?
Chiauranib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
5 participants
Where
1 siteChina
Study dates
9 May 2017to 14 Feb 2019
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or Female, aged ≥ 18 yrs and ≤70 yrs;
  • Histological or cytological confirmation of non-Hodgkin's lymphoma（NHL）, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other aggressive NHLs which determined by the investigator.
  • Patients with NHL refractory to at least 2 different chemotherapies , for which no standard therapy exists;
  • At least 1 lesion can be accurately measured, as defined by Lugano 2014 criteria.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
  • Subjects received anti-cancer therapy (including chemotherapy, radiotherapy, immunotherapy and surgical therapy, et al) should beyond 4 weeks prior to study entry; Subjects received mitomycin chemotherapy should beyond 6 weeks prior to study entry; Subjects received autologous stem cell transplantation should beyond 3 months prior to study entry;
Show all 10Show fewer
  • Laboratory criteria are as follows:
  • Complete blood count: hemoglobin (Hb) ≥90g/L ; absolute neutrophil count (ANC) ≥1.5×109/L ; platelets >=90×109/L Biochemistry test: total bilirubin≦1.5×ULN; alanine aminotransferase(ALT) ,aspartate aminotransferase(AST)≦1.5×ULN; (ALT,AST≦5×ULN if liver involved) ;serum creatinine(cr)≦1.5×ULN; Coagulation test: International Normalized Ratio (INR) < 1.5
  • Life expectancy of at least 12 weeks.
  • Willingness to sign a written informed consent document.

Who cannot join

  • Patients with prior invasive malignancies with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ, unless received curative treatment and with documented evidence of no recurrence in the past five years;
  • Clinical evidence of central nervous system involvement;
  • Have uncontrolled or significant cardiovascular disease, including:
  • Congestive heart failure, unstable angina pectoris, myocardial infarction within 6 months prior to study entry; arrhythmia, or Left Ventricular Ejection Fraction (LVEF) < 50% requiring treatment with agents during screening stage.
  • primary cardiomyopathy(dilated cardiomyopathy, hypertrophic cardiomyocyte, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, et,al)
  • History of significant QT interval prolongation, or Corrected QT Interval (QTc) > 450 ms prior to study entry
Show all 23Show fewer
  • Symptomatic coronary heart disease requiring treatment with agents
  • Uncontrolled hypertension (> 140/90 mmHg) by single agent;
  • Have active bleeding current thrombotic disease, patients with bleeding potential ,or receiving anticoagulation therapy; within 2 months prior to screening;
  • Proteinuria positive(≥1g/24h);
  • History of deep vein thrombosis or pulmonary embolism;
  • Have unsolved toxicities (> grade 1) from prior anti-cancer therapy;
  • Have clinical significant gastrointestinal abnormality, e.g., unable to swallow, chronic diarrhea, ileus, that would impair the ingestion,transportation or absorption of oral agents, or patients undergone gastrectomy;
  • History of organ transplantation or Allogeneic bone marrow transplantation;
  • Major surgery within 6 weeks and minor surgery within 2 weeks prior to screening (excluding placement of vascular access or biopsy) that involved general anaesthesia or respiratory assistance;
  • Serologically positive for HIV, hepatitis B or C, or other serious infectious diseases;
  • History of interstitial lung disease(ILD);
  • Previous treatment with aurora kinase inhibitors;
  • Patients appropriate and ready for autologous stem cell transplantation;
  • Any mental or cognitive disorder, that would impair the ability to understand the informed consent document or the operation and compliance of study;
  • Candidate with drug and alcohol abuse;
  • Participants of reproductive potential not willing to use adequate contraceptive measures for the duration of the study (both male and female participants).Pregnant or breastfeeding women. Female participants must have a negative urinary or serum pregnancy test when done or have evidence of post-menopausal status (Defined as absence of menstruation for greater than 12 months, bilateral oophorectomy or hysterectomy);
  • Any other condition which is inappropriate for the study in the opinion of the investigators.

Trial locations and contacts

1 site in 1 country.

China1 site

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100021

Other trials in China

About this study

Official title: Efficacy and Safety of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma: a Single-arm, Open-label, Multi-site, Exploratory Phase Ib Study

Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora B）、VEGFR/PDGFR/c-Kit、CSF-1R targets.

This clinical trial is studying the efficacy and safety of chiauranib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.

Being tested
Chiauranib
Keywords
Non-Hodgkin's lymphoma, Relapsed/Refractory, Aurora kinase B
Medical subject headings
Lymphoma, Non-Hodgkin, Recurrence, Hereditary Sensory and Autonomic Neuropathies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ChiauranibDrug

    Also called CS2164

    Take 50mg orally once daily

Study groups in NCT03074825
Study groupRoleWhat they receive
chiauranibExperimentalPatients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
Receives: Drug: Chiauranib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall response rate(ORR)

    ORR will be calculated from the data obtained from the end visit

    Measured: assessed up to 2 years

Secondary outcomes (6)

  1. Number of participants with treatment-related adverse events

    measured by adverse events (AE), serious adverse events (SAE), abnormal vital signs，electrocardiograph(ECG) and abnormal laboratory results according to CTCAE V4.03

    Measured: Measured through 2 years

  2. progression-free survival (PFS)

    From date of treatment until the date of first documented progression or date of death from any cause, whichever came first

    Measured: assessed up to 2 years

  3. time to progression(TTP)

    duration from date of treatment until the date of first documented progression

    Measured: through treatment completion, up to 2 years

  4. complete remission rate(CRR)

    Measured: through treatment completion, up to 2 years

  5. duration of response (DOR)

    From the first date of response until the date of first documented progression

    Measured: assessed up to 2 years

  6. overall survival(OS)

    Time from treatment to death from any cause

    Measured: assessed up to 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Mar 2017
  2. Study start9 May 2017
  3. Primary completion15 Aug 2017
  4. Study completion14 Feb 2019

Why it stopped: The results fell short of expectations.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
5 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03074825
Sponsor's protocol ID
CAR103
Status last verified
Jul 2019
First submitted
1 Mar 2017
Last updated
24 Jul 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Chiauranib in people with Non-Hodgkin's Lymphoma, run by Chipscreen Biosciences, Ltd. at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 24 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: The results fell short of expectations.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall response rate(ORR) (time frame: assessed up to 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03074825.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2019.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT03074825 | AzTrials